The global Primary Sclerosing Cholangitis Market is estimated to be valued at US$ 1.98 Mn or Mn in 2023 and is expected to exhibit a CAGR of 7.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
The disease causes bile duct injury and scarring which disrupts the drainage of bile from the liver and leads to buildup of toxicity in the liver. People suffering from PSC have higher chances of developing liver cancer and require liver transplantation.
Market key trends:
One of the key trends in the primary sclerosing cholangitis market is rising research involving fecal microbiota transplantation (FMT). FMT aims to restore gut microbiota dysbiosis in patients with PSC. This has shown promising results in alleviating symptoms and improving liver damage. Studies are ongoing to evaluate its role in modulating the immune system and reducing inflammation in PSC patients. Further research could establish microbiome modulation as an effective treatment strategy for primary sclerosing cholangitis.
Market Key Trends:
Primary Sclerosing Cholangitis market Growth is witnessing increasing adoption of advanced diagnostics techniques and development of novel drugs. Magnetic resonance cholangiopancreatography (MRCP) has emerged as a popular non-invasive imaging technique for diagnosis of PSC. Additionally, researchers are conducting clinical trials for drug candidates targeting specific pathways involved in disease progression. Elafibranor, an agonist of PPARα/δ, is being evaluated in a late-stage trial for treating fibrosis associated with PSC.
SWOT Analysis
Strength: Rising awareness about early diagnosis and treatment. Growing research focus on developing targeted therapies.
Weakness: Lack of approved drugs. Complex etiology makes treatment challenging.
Opportunity: Unmet need warrants development of novel treatment strategies. Advancements in diagnostics and imaging modalities.
Threats: Success rate of late-stage clinical trials. High costs associated with long-term management.
Key Takeaways
The global Primary Sclerosing Cholangitis market is expected to witness high growth, exhibiting CAGR of 7.6% over the forecast period, due to increasing research on targeted therapies.
Regionally, North America dominates the global PSC market currently. This is attributed to growing patient awareness levels regarding symptoms and treatment options. Asia Pacific is expected to emerge as the fastest growing market over the coming years supported by rising healthcare expenditure and increasing adoption of advanced diagnostic modalities.
Key players operating in the Primary Sclerosing Cholangitis market are Acorda Therapeutics, Inc., Gilead Sciences, Inc., NGM Biopharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., Dr. Falk Pharma GmbH, Allergan Plc., Shire Plc., Durect Corporation, Conatus Pharmaceuticals, Inc., Sirnaomics, Inc., and Shenzhen HighTide Biopharmaceutical Ltd.
Read Our More Blogs : https://www.ukwebwire.com/primary-sclerosing-cholangitis-market-size-share-outlook-and-trend/
Comments
0 comment